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Abstract
Background: Doubts remain over the use of the ECG in identifying those with increased left
ventricular (LV) mass. This is especially so in young individuals, despite their high prevalence of ECG
criteria for LV hypertrophy. We performed a study using cardiovascular magnetic resonance
(CMR), which provides an in vivo non-invasive gold standard method of measuring LV mass, allowing
accurate assessment of electrocardiography as a tool for defining LV hypertrophy in the young.
Methods and results: Standard 12-lead ECGs were obtained from 101 Caucasian male army
recruits aged (mean ± SEM) 19.7 ± 0.2 years. LV mass was measured using CMR. LV mass indexed
to body surface area demonstrated no significant correlation with the Cornell Amplitude criteria
or Cornell Product for LV hypertrophy. Moderate correlations were seen with the Sokolow-Lyon
Amplitude (0.28) and Sokolow-Lyon Product (0.284). Defining LV hypertrophy as a body surface
area indexed left ventricular mass of 93 g/m2, calculated sensitivities [and specificities] were as
follows; 38.7% [74.3%] for the Sokolow-Lyon criteria, 43.4% [61.4%] for the Sokolow-Lyon
Product, 19.4% [91.4%] for Cornell Amplitude, and 22.6% [85.7%] for Cornell Product. These
values are substantially less than those reported for older age groups.
Conclusion: ECG criteria for LV hypertrophy may have little value in determining LV mass or the
presence of LV hypertrophy in young fit males.
Background
Cardiovascular risk rises with increasing left ventricular
(LV) mass [1], with dichotomously-defined LV hypertro-
phy a powerful and independent risk factor in a variety of
disease states [2-4], and even amongst the healthy and
normotensive [1,5]. Electrocardiography (ECG) has been
used to help identify increased LV mass and thus cardio-
vascular risk[6,7]. However, doubts remain over the sensi-
tivity and, increasingly, specificity of the ECG in
identifying those with increased LV mass [6,8], especially
in younger individuals [9-11]. Indeed, in 300 healthy
post-pubertal boys (mean age 16 years) with a sedentary
lifestyle, 23% fulfilled the Sokolow-Lyon Amplitude crite-
ria for LV hypertrophy [10].
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In an effort to resolve these issues, attempts have been
made to define the sensitivity and specificity of ECG crite-
ria in identifying LV hypertrophy, by comparison with
echocardiographic estimates of LV mass [12-16]. How-
ever, few have attempted to address this issue in the young
and fit [11,17]. Further, when applied to the individual,
echocardiographic measures of LV mass are imprecise as
they assume a uniform LV shape and apply a cubing
mathematical formula to derive an estimation of LV mass.
The advent of cardiovascular magnetic resonance (CMR)
now offers a gold standard in the accurate quantification
of LV mass [18], and studies confirm the weakness of
echocardiography in this regard [19]. For this reason,
CMR has been used to assess the validity of ECG-derived
indices of LV mass; but to date, only in small cohorts of
older adults [20,21].
Thus, we have used CMR to clarify whether the high prev-
alence of ECG-defined LV hypertrophy in the young truly
represents the prevalence of LV hypertrophy. We have
assessed four different criteria: the Sokolow-Lyon Ampli-
tude [22], Cornell Amplitude[23], Sokolow-Lyon Product
and Cornell Product [24] in diagnosing LV hypertrophy in
a large sample of young male army recruits.
Methods
This study complies with the Declaration of Helsinki and
had appropriate ethics approval (Defence Medical Serv-
ices Clinical Research Committee). Written informed con-
sent was obtained from all participants.
Study subjects
Subjects were enrolled in the LARGE Heart study,
described in detail elsewhere [25]. In brief, consecutive
healthy young Caucasian male army recruits were studied
at entry to the Army Training Regiment, Lichfield, United
Kingdom between July 2002 and April 2004. Any poten-
tial subjects with hypertension or regular medication use
were excluded prior to the start of the study. Subject
height and weight were recorded and body surface area
(BSA) estimated using the Dubois formula: BSA =
0.20247 × height (m)0.725 × weight (Kg)0.425. LV mass was
quantified using CMR, and standard resting 12-lead elec-
trocardiography was performed.
CMR assessment of LV mass
Imaging was performed using a mobile 1.5 Tesla Siemens
Sonata CMR scanner applying protocols previously
described [26]. In brief, the LV short axis was identified by
first piloting a vertical long axis (VLA) plane from the
transaxial plane. The horizontal long axis (HLA) plane
was imaged, and from this a stack of short axis (SA)
images was obtained during breath-holding, covering the
length of the LV. ECG-gated cine images were used in
order to measure the LV mass at end-diastole. The tempo-
ral resolution was 21.6 ms. The in plane pixel size was 2.1
× 1.3 mm. All images were acquired using a steady state
free precession (SSFP) sequence. Image analysis was per-
formed by one investigator (JP) blind to other study data,
using CMRtools (Cardiovascular Imaging Solutions, Lon-
don, UK). The area of myocardium was calculated for each
SA slice and, using Simpson's method, LV myocardial vol-
ume calculated. Trabeculae were included in the assess-
ment of LV mass, but papillary muscles were excluded.
This volume was then multiplied by myocardial tissue
specific density (1.05 g/cm3). LV mass indexed to BSA was
used in statistical analysis. All measurements of LV mass
presented here were before a period of physical training
and have been presented previously [25].
Electrocardiography
Electrocardiographic assessment was performed immedi-
ately prior to scanning in a randomly-selected subgroup
of individuals. A standard resting 12-lead recording was
made during quiet respiration, with subjects in a supine
position. The ECG was recorded at 25 mm/s and 0.1 mV/
mm standardisation with a MAC 5000 resting ECG system
(GE Medical Systems, UK). All ECG characteristics were
determined from digital data using an appropriate soft-
ware package (Cardiosoft, GE Medical Systems). From
these measurements, one observer blinded to CMR data
calculated 4 ECG criteria: Sokolow-Lyon Amplitude [22],
Sokolow-Lyon Product [24], Cornell Amplitude [27] and
Cornell Product [24]. LV hypertrophy was defined as a
Sokolow-Lyon Amplitude of [SV1 + RV5 or RV6] ≥ 35 mm;
a Sokolow-Lyon Product of [(SV1 + RV5) or (RV6) × QRS
duration] ≥ 2940 mm·ms [20]; a Cornell Amplitude of
[RaVL + SV3] ≥ 28 mm and a Cornell Product of [(RaVL +
SV3) × QRS duration] ≥ 2440 mm·ms.
Statistical analysis
Data were analysed using SPSS software (version 12.0.1).
The relationship between LV mass indexed to BSA
(indexed LV mass) and Sokolow-Lyon Amplitude,
Sokolow-Lyon Product, Cornell Amplitude, and Cornell
Product were assessed using Pearson's correlation coeffi-
cients. To assess the performance of different ECG criteria,
LV hypertrophy was defined using three different criteria:
The lowest threshold limit for 'acceptable' LV mass in this
study was one defined using CMR in a study of 30 normal
men, albeit of greater age (20–65 years) this being ≤  83 g/
m2 [20,28]. However, 63% of our subjects had values of
indexed LV mass greater than this. As a result, we studied
two other thresholds; the first being 2 standard deviations
(SD) above the mean for our group of subjects (108 g/
m2). The other was based on a study that tried to define
normal ranges according to age ranges. The lowest age
range for males in that study was 20–29 and gave a cut off
value of 93 g/m2 2-SD above the mean [29]. Sensitivities
and specificities for the existing cut off values for theJournal of Cardiovascular Magnetic Resonance 2009, 11:2 http://www.jcmr-online.com/content/11/1/2
Page 3 of 7
(page number not for citation purposes)
Sokolow-Lyon Amplitude, Sokolow-Lyon Product, Cor-
nell Amplitude, and Cornell Product were calculated for
each of the three cut off values of LV hypertrophy. Per-
formance of the different ECG criteria over the full range
of amplitudes was assessed using receiver operator curve
(ROC) characteristics. Curves were constructed using the
three different cut off values for LV hypertrophy. Signifi-
cance tests were performed to assess the difference
between the area under the curve for the ROC curve and
the area under the line of no discrimination (0.5). The
mean indexed LV mass of the participants with and with-
out ECG-defined LV hypertrophy were compared using an
unpaired sample t-test.
Results
One hundred and one subjects were enrolled, whose
(mean ± SD) age was 19.7 ± 2.3 years, height 178.4 + 7.0
cm, weight 73.6 ± 9.8 kg, systolic blood pressure 122.1 ±
16.9 mm Hg, diastolic blood pressure 68.4 ± 10.5 mm Hg,
LV mass 168.0 ± 24.9 g and LV mass indexed to BSA 87.7
± 10.3 g/m2. Prevalence of ECG-defined LV hypertrophy
was 29.7%, 41.6%, 11.9% and 16.8% for Sokolow-Lyon
Amplitude, Sokolow-Lyon Product, Cornell Amplitude
and Cornell Product criteria respectively.
We assessed the correlation of Sokolow-Lyon Amplitude,
Sokolow-Lyon Product, Cornell Amplitude and Cornell
Product with LV mass index (Table 1). A significant asso-
ciation was only demonstrable with the Sokolow-Lyon
Amplitude and Product (R = 0.280 and 0.284 respec-
tively).
Sensitivity and specificity of the four ECG criteria in iden-
tifying CMR-determined LV hypertrophy was then
addressed using 83 g/m2 as a threshold for LV hypertrophy
(Table 2). All four ECG criteria demonstrate low sensitiv-
ity (14.1% to 43.8%) with variable specificities (62.2% to
91.9%). The sensitivity of these criteria is not impressive
at the threshold of 93 g/m2 (sensitivity from 19.4% to
43.4% and specificity from 61.4% to 91.4%). On moving
the threshold up to 108 g/m2, sensitivity improves (up to
75% for the Sokolow-Lyon criteria) with a further fall in
specificity (59.8% to 88.7%). The prevalence of LV hyper-
trophy for the cut off values was 63% at 83 g/m2, 31% at
93 g/m2, and 4% at 108 g/m2. ROC curves for the
Sokolow-Lyon criteria were constructed using the three
different cut off values for LV hypertrophy (Figures 1, 2
and 3). There was no statistically significant difference
between the area under the curve for any of the amplitude
criteria and the line of no discrimination (Table 3).
Finally, we calculated the mean LV mass index for those
subjects categorised as having or lacking LV hypertrophy
as defined by each of the four ECG criteria (Table 4). Only
using the Sokolow-Lyon Amplitude was there a significant
difference in LV mass index between ECG positive and
ECG negative.
Discussion
This is the first study to examine the validity of electrocar-
diography in the determination of LV hypertrophy in
young healthy males, using CMR-measured (as opposed
to echocardiographically-imputed) LV mass as the gold-
standard. It demonstrates the poor sensitivity of estab-
lished ECG criteria in identifying LV hypertrophy in such
individuals.
Our data confirm the high incidence of electrocardio-
graphically-defined LV hypertrophy amongst the young
and healthy. Twenty-nine percent had LV hypertrophy as
defined by Sokolow-Lyon ECG Amplitude criteria, a figure
similar to the 23% incidence previously observed in
healthy teenage non-athletes [10]. One would expect the
incidence of physiological left ventricular hypertrophy to
be higher in this cohort as army recruits will be more ath-
letic than the general population. Other studies have
showed a higher prevalence of ECG defined left ventricu-
lar hypertrophy in the athletic rising to 50% amongst 172
teenage soccer players [11], and 45% amongst 1000 teen-
age elite athletes [10].
The amplitude criteria assessed here were all derived using
various markers to indicate LV hypertrophy, but all in
older age groups, and before the advent of CMR. Echocar-
diography or autopsy were used to define or validate the
criteria tested here, and in the case of the Sokolow Lyon,
Table 1: Correlation with LV mass indexed to BSA
Criteria Pearson Correlation Coefficient P-value
Sokolow-Lyon Amplitude
(mm)
0.280 0.005
Sokolow-Lyon Product
(mm·ms)
0.284 0.004
Cornell Amplitude
(mm)
0.065 0.516
Cornell Product
(mm·ms)
0.097 0.336Journal of Cardiovascular Magnetic Resonance 2009, 11:2 http://www.jcmr-online.com/content/11/1/2
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the criteria were based on clinical features predominantly
[30]. Most of the subjects in these validation studies
would have had pathological LV hypertrophy, unlike in
this study.
The CMR data presented here shows some striking differ-
ences to the validation studies, and other studies assessing
ECG criteria for LV hypertrophy. Across a range of past
studies and methods, we see generally poor sensitivities,
but relatively good specificities, with correlation coeffi-
cients clustering between 0.5 and 0.6, but these have all
been done in older subjects, many of whom have estab-
lished cardiac pathology [23,27,24,11,16]. The correla-
tion coefficients are much weaker in this cohort despite
similar sample sizes to older studies. Only the Sokolow-
Lyon Amplitude and Product show a significant correla-
tion with indexed LV mass, and even this is weak. No rela-
tionship is seen with the Cornell Amplitude or Cornell
Product. This implies that in a population of young fit
males, existing ECG amplitude criteria do little to indicate
LV mass. Of the existing amplitude criteria, the Sokolow-
Lyon Amplitude and Product may give some indication of
LV mass, but much less so than in a group of older adults
with other evidence of underlying cardiac disease. It is
unclear why the Sokolow Lyon criteria should show a
stronger relationship in the young to the Cornell criteria.
There is likely to be a feature in this younger cohort which
diminish the use of the Cornell criteria, such as body habi-
tus. The BSA measurements confirm that the individuals
in this study are very thin chested which would impact on
the specificity of some of the ECG criteria. One could
speculate that the Cornell criteria are better at detecting
pathological left ventricular hypertrophy rather than
physiological hypertrophy which is likely to be the pre-
dominant form in this group and hence these results.
According to these results, while the Sokolow Lyon criteria
may give some indication of LV mass, they are not likely
to demonstrate whether this is pathological, and is
unlikely to be of any clinical use in this age group.
Some recent studies have tried to establish normal ranges
for LV mass stratified by age group and sex. The cut off
used in this study used an indexed LV mass cut off of 83
ROC curves with a cut off value of 83 g/m2 for LV hypertro- phy Figure 1
ROC curves with a cut off value of 83 g/m2 for LV 
hypertrophy.
ROC curves with a cut off value of 93 g/m2 for LV hypertro- phy Figure 2
ROC curves with a cut off value of 93 g/m2 for LV 
hypertrophy.
ROC curves with a cut off value of 108 g/m2 for LV hypertro- phy Figure 3
ROC curves with a cut off value of 108 g/m2 for LV 
hypertrophy.Journal of Cardiovascular Magnetic Resonance 2009, 11:2 http://www.jcmr-online.com/content/11/1/2
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g/m2, based on a study of 60 men with a mean age of 43
years[28]. A more recent study has tried to define indexed
LV mass values using SSFP CMR stratified by age and sex
[29]. In this study an upper limit of 93 g/m2 is inferred for
men aged 20–29. This was based on a value 2 standard
deviations (SD) above the mean from a sample of 10 men
aged 20–29 years. That study did not include those aged
under 20 years, the age of many of the participants in our
report but for the purposes of this study provided a rea-
sonable approximation. Unfortunately most of these esti-
mates are based on small cohorts. In this cohort, the value
2-SD above the upper limit of normal was 108 g/m2,
which is much higher than either of the quoted figures.
Participants in this study are army recruits and may be
more active than their peers, so this higher cut off may
represent an element of physiological LV hypertrophy
seen in athletes [11,17]. In fact in the analysis, there was
little evidence of pathological forms of LV hypertrophy
such as hypertrophic cardiomyopathy, so most of the
increased LV mass is likely to be physiological in this
cohort.
Despite the absence of an established mass cut off in this
age group, across the three mass cut-offs for LV hypertro-
phy, the ROC curves demonstrate that all the ECG criteria
are poor at delineating LV hypertrophy. One pays the
price either with sensitivity or specificity over a range of
amplitudes. With none of the cut off values for indexed LV
mass was there a statistically significant difference
between the line of no discrimination.
We did show that participants who were Sokolow-Lyon
Amplitude positive for LV hypertrophy did have a higher
LV mass, but this is not surprising considering the slight
positive correlation between indexed LV mass and
Sokolow-Lyon Amplitude. This must, however, be inter-
preted in the context of the ROC curves for these criteria,
which imply there is little practical use for the Sokolow-
Lyon Amplitude in the diagnosis of LV hypertrophy in the
young.
There are a number of strengths to this study. It has used
CMR rather than echocardiography to determine LV mass.
It has used this gold standard to validate and assess these
commonly used ECG criteria in population of fit young
males unlike the majority of previous work, which has
been in an older population, who often have disease.
There are, however, some limitations. The sample is rela-
tively small, and the subjects are all male. It is difficult to
perform such a study when there is no well-established
cut off for normal LV mass in young males. This became
particularly apparent when analysing the participants
who had an LV mass 2 SD above the mean for this group
where only four subjects were present. In such a popula-
tion increased LV mass in itself may be marker of health
rather than disease. The population is white and does not
account for racial differences [31].
To conclude, commonly used amplitude criteria may have
little practical use in detecting LV hypertrophy in the
young. In particular, Cornell Amplitude and Cornell
Product have little relationship with LV mass in a group of
Table 2: Sensitivities and specificities according to three partitions values of LV mass indexed to BSA (sens = sensitivity, spec = 
specificity).
LV mass indexed to BSA partition values
83 g/m2 93 g/m2 108 g/m2
ECG Criteria Sens
(%)
Spec
(%)
Sens
(%)
Spec
(%)
Sens
(%)
Spec
(%)
Sokolow-Lyon Amplitude
>35 mm
35.9 81.1 38.7 74.3 50.0 71.1
Sokolow-Lyon Product
>2940 mm·ms
43.8 62.2 43.4 61.4 75.0 59.8
Cornell Amplitude
>28 mm
14.1 91.9 19.4 91.4 25.0 88.7
Cornell Product
>2440 mm·ms
18.8 86.5 22.6 85.7 25.0 83.5
Table 3: Area under curve values from ROC curve analysis.
Area Under Curve (significance)
LVH Cut off Value: 83 g/m2 93 g/m2 108 g/m2
Sokolow-Lyon Amplitude 0.592 (0.13) 0.613 (0.07) 0.722 (0.13)
Sokolow-Lyon Product 0.610 (0.07) 0.618 (0.06) 0.678 (0.23)
Cornell Amplitude 0.494 (0.92) 0.524 (0.71) 0.469 (0.83)
Cornell Product 0.514 (0.81) 0.533 (0.60) 0.454 (0.75)Journal of Cardiovascular Magnetic Resonance 2009, 11:2 http://www.jcmr-online.com/content/11/1/2
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young males. Whilst the Sokolow-Lyon Amplitude has a
(weak) correlation with LV mass, the price is paid in terms
of specificity and sensitivity when more stringent criteria
defining LVH are applied.
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